Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection

Abstract

A combination of zidovudine, didanosine, and lamivudine was used to treat 10 patients with primary human immunodeficiency virus type 1 (H1V-1) infection 5-28 days after the onset of symptoms. When therapy began, the mean plasma H1V-1 RNA level was 5.31 ± 0.33 log10 copies/mL and the mean CD4 T cell count was 630 ± 112 x 106/L. The plasma HIV-1 RNA level decreased rapidly, and levels dropped below the cutoff in each case after 108 ± 32 days. Lymph nodes from 5 patients were biopsied before therapy and during follow-up. Infectious HIV-1 could not be cultivated from any lymph node mononuclear cells taken on day 90, and HIV-1 RNA was at very low levels in lymph nodes after 1 year. In some eases, waning of the antibody response to HIV-1 was shown by Western blot after several months of undetectable plasma RNA. These data demonstrate that triple-drug therapy has a potent antiviral effect during primary HIV-1 infection.